Temozolomide regresses a doxorubicin‐resistant undifferentiated spindle‐cell sarcoma patient‐derived orthotopic xenograft (PDOX): precision‐oncology nude‐mouse model matching the patient with effective therapy. Issue 8 (8th May 2018)
- Record Type:
- Journal Article
- Title:
- Temozolomide regresses a doxorubicin‐resistant undifferentiated spindle‐cell sarcoma patient‐derived orthotopic xenograft (PDOX): precision‐oncology nude‐mouse model matching the patient with effective therapy. Issue 8 (8th May 2018)
- Main Title:
- Temozolomide regresses a doxorubicin‐resistant undifferentiated spindle‐cell sarcoma patient‐derived orthotopic xenograft (PDOX): precision‐oncology nude‐mouse model matching the patient with effective therapy
- Authors:
- Igarashi, Kentaro
Kawaguchi, Kei
Kiyuna, Tasuku
Miyake, Kentaro
Miyake, Masuyo
Li, Yunfeng
Nelson, Scott D.
Dry, Sarah M.
Singh, Arun S.
Elliott, Irmina A.
Russell, Tara A.
Eckardt, Mark A.
Yamamoto, Norio
Hayashi, Katsuhiro
Kimura, Hiroaki
Miwa, Shinji
Tsuchiya, Hiroyuki
Eilber, Fritz C.
Hoffman, Robert M. - Abstract:
- Abstract: Undifferentiated spindle‐cell sarcoma (USCS) is a recalcitrant cancer, resistant to conventional chemotherapy. A patient with high‐grade USCS from a striated muscle was implanted orthotopically in the right biceps femoris muscle of mice to establish a patient‐derived orthotopic xenograft (PDOX) model. The PDOX models were randomized into the following groups when tumor volume reached 100 mm 3 : G1, control without treatment; G2, doxorubicin (DOX) (3 mg/kg, intraperitoneal [i.p.] injection, weekly, for 2 weeks); G3, temozolomide (TEM) (25 mg/kg, p.o., daily, for 14 days). Tumor size and body weight were measured with calipers and a digital balance twice a week. TEM significantly inhibited tumor volume growth compared to the untreated control and the DOX‐treated group on day 14 after treatment initiation: control (G1): 343 ± 78 mm 3 ; DOX (G2): 308 ± 31 mm 3, P = 0.272; TEM (G3): 85 ± 21 mm 3, P < 0.0001. TEM significantly regressed the tumor volume compared to day 0 ( P = 0.019). There were no animal deaths in any group. The body weight of treated mice was not significantly different in any group. Tumors treated with DOX were comprised of spindle‐shaped viable cells without apparent necrosis or inflammatory changes. In contrast, tumors treated with TEM showed extensive tumor necrosis. The present study demonstrates the potential power of matching the patient with an effective drug and saving the patient needless toxicity from ineffective drugs. Abstract : USCSAbstract: Undifferentiated spindle‐cell sarcoma (USCS) is a recalcitrant cancer, resistant to conventional chemotherapy. A patient with high‐grade USCS from a striated muscle was implanted orthotopically in the right biceps femoris muscle of mice to establish a patient‐derived orthotopic xenograft (PDOX) model. The PDOX models were randomized into the following groups when tumor volume reached 100 mm 3 : G1, control without treatment; G2, doxorubicin (DOX) (3 mg/kg, intraperitoneal [i.p.] injection, weekly, for 2 weeks); G3, temozolomide (TEM) (25 mg/kg, p.o., daily, for 14 days). Tumor size and body weight were measured with calipers and a digital balance twice a week. TEM significantly inhibited tumor volume growth compared to the untreated control and the DOX‐treated group on day 14 after treatment initiation: control (G1): 343 ± 78 mm 3 ; DOX (G2): 308 ± 31 mm 3, P = 0.272; TEM (G3): 85 ± 21 mm 3, P < 0.0001. TEM significantly regressed the tumor volume compared to day 0 ( P = 0.019). There were no animal deaths in any group. The body weight of treated mice was not significantly different in any group. Tumors treated with DOX were comprised of spindle‐shaped viable cells without apparent necrosis or inflammatory changes. In contrast, tumors treated with TEM showed extensive tumor necrosis. The present study demonstrates the potential power of matching the patient with an effective drug and saving the patient needless toxicity from ineffective drugs. Abstract : USCS PDOX histology in treated and untreated tumor. A, Hematoxylin and eosin (H&E)‐stained section of the original patient's tumor. B, Untreated PDOX tumor. C, PDOX tumor treated with DOX. D, PDOX tumor treated with TEM. Scale bars: 80 µm. … (more)
- Is Part Of:
- Journal of cellular biochemistry. Volume 119:Issue 8(2018)
- Journal:
- Journal of cellular biochemistry
- Issue:
- Volume 119:Issue 8(2018)
- Issue Display:
- Volume 119, Issue 8 (2018)
- Year:
- 2018
- Volume:
- 119
- Issue:
- 8
- Issue Sort Value:
- 2018-0119-0008-0000
- Page Start:
- 6598
- Page End:
- 6603
- Publication Date:
- 2018-05-08
- Subjects:
- doxorubicin -- efficacy -- individualized therapy -- nude mice -- PDOX -- precision medicine -- temozolomide
Cytochemistry -- Periodicals
572 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-4644 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/jcb.26792 ↗
- Languages:
- English
- ISSNs:
- 0730-2312
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4955.010000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24387.xml